Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Alnylam Pharmaceuticals Surges to 439th in Trading Volume with $185 Million Turnover

Market BriefMonday, Apr 21, 2025 8:00 pm ET

1min read

On April 21, 2025, Alnylam Pharmaceuticals (ALNY) experienced a significant trading day with a turnover of $185 million, marking a 31.78% increase from the previous day. This surge placed ALNY at the 439th position in terms of trading volume for the day. However, the stock closed with a slight decline of 0.77%.

Analysts have shown a strong bullish sentiment towards Alnylam Pharmaceuticals. Over the past three months, 22 analysts have rated the stock, with 18 recommending a 'Buy' and 4 suggesting a 'Hold'. There are no 'Sell' ratings. This consensus reflects a positive outlook on the company's future performance.

The average 12-month price target for Alnylam Pharmaceuticals is $321.86, indicating a potential upside of 37.22% from the current price. The highest price target among analysts is $500.00, while the lowest is $206.00. This wide range suggests varying levels of optimism about the stock's potential growth.

Several analysts have reiterated their positive stance on Alnylam Pharmaceuticals. For instance, Piper Sandler maintained a 'Buy' rating with a price target of $304, representing a 29.60% upside. Similarly, Bernstein reiterated a 'Buy' rating with a price target of $305, indicating a 30.03% upside. J.P. Morgan upgraded Alnylam Pharmaceuticals to 'Overweight' from 'Neutral', with a price target increased from $280 to $328, reflecting a 39.84% upside.

TD Cowen also reiterated a 'Buy' rating with a price target of $371, suggesting a 58.17% upside. These ratings underscore the confidence analysts have in Alnylam Pharmaceuticals' growth prospects, driven by recent FDA approvals and promising clinical results.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.